Previous 10 | Next 10 |
The following slide deck was published by MEI Pharma, Inc. in conjunction with this Read more ...
SAN DIEGO , Sept. 15, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Brian T. Powl as senior vice president, marketing, a new role that will report t...
MEI Pharma, Inc. (MEIP) Q4 2020 Earnings Conference Call September 9, 2020 5:00 P.M. ET Company Participants David Walsey - Vice President, Investor Relations and Corporate Communications Brian Drazba - Chief Financial Officer Dan Gold - President and Chief Executive Officer C...
MEI Pharma (NASDAQ: MEIP ) : FY GAAP EPS of -$0.51 misses by $0.36 . More news on: MEI Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , Sept. 9, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30 , 2020. "This past year was marked by progress on multiple f...
SAN DIEGO , Sept. 4, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the following upcoming virtual investor conferences: Wells Fargo 2020 Virtual Hea...
SAN DIEGO , Sept. 2, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2020 fiscal year end financial results after the close of the U.S. financial m...
New York, New York--(Newsfile Corp. - August 11, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MEI Pharma, Inc. ("MEI Pharma" or the "Company") (NASDAQ: MEIP) of the October 9, 2020 deadline to seek the role of lead plaintiff in a federal ...
SAN DIEGO , Aug. 4, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company ove...
Our analysis concludes MEI Pharma Inc.'s (MEIP) recent sell-off is materially overdone. MEIP's sell-off is (most likely) due to a recent unexpected announcement of the discontinuation of MEIP's most clinically advanced oncology program (Pracinostat) in development by MEIP's licensee. However, ...
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...